Morena Sallabanda Hajro

Dr. Morena Sallabanda Hajro

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Cureus
Verified
Journal Article
Open access
ELEduardo E Lovo
Eduardo E Lovo
AMAlejandra Moreira
Alejandra Moreira
KBKaory C. Barahona
Kaory C. Barahona
JRJuliana Ramirez
Juliana Ramirez
FCFidel Campos
Fidel Campos
KSKita Sallabanda
Kita Sallabanda
Glioblastoma multiforme (GBM) is the most common and lethal primary malignancy of the central nervous system. Despite standard therapy protocols, such as aggressive surgical resection, radiotherapy, and chemotherapy, GBM's aggressive nature produces low survival rates. Tumor recurrence and progression are nearly universal. Stereotactic radiosurgery (SRS) has been studied as an alternative treatment for recurrent GBM as a minimally invasive option that might prolong survival. The objective of this retrospective study was to evaluate the efficacy of SRS as a treatment modality considering overall survival (OS) in patients with GBM who had tumor recurrence and were treated with SRS in three different institutions. We retrospectively reviewed patients who received SRS for recurrent GBM between 1992 and 2020. A total of 46 patients were included in this study. We recorded age at diagnosis, the extent of surgical resection, radiation treatment, chemotherapy regimen, Karnofsky Performance Status at the time of SRS and at last follow-up, use of adjuvant chemotherapy after SRS, and response evaluation criteria in solid tumors. Primary endpoints were OS after initial diagnosis and OS from the date of the SRS procedure. Patients received SRS at a median of 10 months (range, 1 to 94 months) after their initial diagnoses. Median follow-up was seven months from the time of SRS and 22.8 months since diagnosis. The estimated median OS for all patients was nine months (range, 1 to 42 months) after SRS and 23.8 months (range, 4 to 102 months) after diagnosis. Median OS after SRS was seven months for patients treated from 1992 to 2011 and nine months for those treated from 2012 to 2020 (p = 0.008; X2 = 7.008). Median OS for younger patients (i.e., those aged 50 years; p = 0.04; X2 = 3.870). Patients who received SRS after 10 months since diagnosis had a median OS of 36.2 months versus those who received SRS sooner than 10 months, who had an OS of 15 months (p = 0.004; X2 = 8.145). Radiosurgery doses larger than 15 Gy correlated with a median survival of nine months versus seven months in those treated with doses <15 Gy (p = 0.01; X2 = 6.756). Lastly, patients who received adjuvant bevacizumab (BEV) and or chemotherapy after SRS had a median survival of 12 months versus seven months for patients who did not receive any additional therapy after SRS (p = 0.04; X2 = 4.196). SRS focal recurrent GBM in selected patients may improve OS, especially when combined with adjuvant therapy such as BEV and chemotherapy. Other prognostic variables proved relevant such as patients' age, the dose delivered, and surgery-to-SRS time that translates to the time of recurrence. Our results were consistent with the published literature and added to the accumulating evidence regarding SRS in recurrent GBM; however, extensive, multi-center studies are required to make definitive recommendations on this treatment approach.

2 March 2020 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MHMorena Sallabanda Hajro
Morena Sallabanda Hajro
MGM. I. García-Berrocal
M. I. García-Berrocal
JRJesús Romero
Jesús Romero
VGV. García-Jarabo
V. García-Jarabo
MEM. J. Expósito
M. J. Expósito
MMM. R. Magallón
M. R. Magallón

31 December 2019 in Cureus
Verified
Journal Article
Open access
PDF file
KSKita Sallabanda
Kita Sallabanda
LYLoreto Yañez
Loreto Yañez
MHMorena Sallabanda Hajro
Morena Sallabanda Hajro
MSMarcos Santos
Marcos Santos
FMFelipe Ángel Calvo Manuel
Felipe Ángel Calvo Manuel
HMHugo Marsiglia
Hugo Marsiglia
High-grade gliomas (HGG) are the most frequent primary central nervous system tumors; treatment of HCGs includes surgery and post-operative conformal radiotherapy associated with temozolomide (TMZ or procarbazine/lomustine/vincristine [PCV], specifically in patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas). However, recurrence is common. Re-irradiation has been utilized in this setting for years and remains a feasible option, although there is always a concern regarding toxicity. Modern high-precision conformal techniques, including stereotactic radiosurgery (SRS), could improve the therapeutic ratio by delivering high biologically equivalent doses while reducing high-dose radiotherapy (RT) to normal brain tissue. In this paper, we present the results obtained after prolonged follow-up in patients who underwent SRS as a treatment for recurrent high-grade gliomas at San Francisco Hospital in Madrid, Spain

8 August 2021 in Cureus
Verified
Journal Article
Open access
MHMorena Sallabanda Hajro
Morena Sallabanda Hajro
RGRafael Garcia
Rafael Garcia
LLLuis Lorenzana
Luis Lorenzana
ISIciar Santaolalla
Iciar Santaolalla
JAJavier Abarca-Olivas
Javier Abarca-Olivas
KSKita Sallabanda
Kita Sallabanda
The aim of this study is to determine the efficacy and safety of CyberKnife® (Accuray, Inc., Sunnyvale, CA) hypofractionated radiosurgery (HfRS) in the treatment of chordomas and chondrosarcomas. A total of 24 patients retrospectively identified with chordomas (19 patients) or chondrosarcomas (five patients) were treated between 2012 and 2019 with HfRS as monotherapy or an adjuvant, rescue, or combination therapy. Tumors were located in the skull base (75%) and vertebral spine (25%). Of these, 19 patients underwent previous partial resection and four patients received previous conventional external beam radiation therapy (EBRT) (60-74 Gy). Exclusive or rescue HfRS (20 patients) was administered in five fractions with a median dose of 37.5 Gy (30-40 Gy). Combined tomotherapy-EBRT treatment (median dose: 54 Gy) and HfRS (16.5-30 Gy in 3-12 fractions) were performed in four patients with bulky chordomas. The median follow-up from HfRS was 28 months. During clinical follow-up, no deaths were registered with overall survival (OS) of 100% and the actuarial local recurrence-free survival (LRFS) was 93% at one year, 85% at three years, and 68% at five years. Acute toxicity related to HfRS was present in a single patient. It is seen that HfRS is effective and safe for chordomas and chondrosarcomas, with rates of LRFS comparable to other radiation modalities.

25 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MHMorena Sallabanda Hajro
Morena Sallabanda Hajro
JVJuan Antonio Vera-Sánchez
Juan Antonio Vera-Sánchez
JPJuan María Pérez
Juan María Pérez
RMRaúl Matute
Raúl Matute
MMMarta Montero
Marta Montero
RMRaymond Miralbell
Raymond Miralbell
(1) Background: Our purpose is to describe the design of a phase II clinical trial on 5-fraction proton therapy for chordomas and chondrosarcomas of the skull base and to present early results in terms of local control and clinical tolerance of the first prospective series. (2) Methods: A dose of 37.5 GyRBE in five fractions was proposed for chordomas and 35 GyRBE in five fractions for chondrosarcomas. The established inclusion criteria are age ≥ 18 years, Karnofsky Performance Status ≥ 70%, clinical target volume up to 50 cc, and compliance with dose restrictions to the critical organs. Pencil beam scanning was used for treatment planning, employing four to six beams. (3) Results: A total of 11 patients (6 chordomas and 5 chondrosarcomas) were included. The median follow-up was 12 months (9–15 months) with 100% local control. Acute grade I–II headache (64%), grade I asthenia and alopecia (45%), grade I nausea (27%), and grade I dysphagia (18%) were described. Late toxicity was present in two patients with grade 3 temporal lobe necrosis. (4) Conclusions: Hypofractionated proton therapy is showing encouraging preliminary results. However, to fully assess the efficacy of this therapeutic approach, future trials with adequate sample sizes and extended follow-ups are necessary.

30 September 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LPLuis Real Peña
Luis Real Peña
MHMorena Sallabanda Hajro
Morena Sallabanda Hajro
MMMarta Quirós Marti
Marta Quirós Marti
KSKita Sallabanda
Kita Sallabanda
Background: Stereotactic radiosurgery (SRS) is an established treatment option for medically refractory trigeminal neuralgia (TN). However, clinical evidence regarding dedicated gyroscopic radiosurgery systems remains limited. This study aimed to evaluate the efficacy, latency of response, safety, retreatment rate, and potential clinical and dosimetric predictors of outcome following ZAP-X gyroscopic radiosurgery for TN. Methods: A consecutive series of patients with pharmacologically refractory TN treated with ZAP-X gyroscopic radiosurgery between February 2023 and September 2025 was analyzed. Treatment consisted of a single isocenter targeting approximately 5 mm of the cisternal-retrogasserian trigeminal nerve, with a maximum dose of 90 Gy and a V70 Gy coverage objective ≥ 50%, using 4 or 5 mm collimators. Pain outcome was assessed using the Barrow Neurological Institute Pain Intensity Scale (BNI), and sensory toxicity was evaluated using the BNI Facial Numbness Scale. Clinical and treatment-related predictors of failure and retreatment were explored using binary logistic regression. Results: Following radiosurgery, 87.5% of patients achieved satisfactory pain control (BNI I–IIIb; 95% CI, 78.8–96.2%), with a significant overall improvement in BNI score compared with baseline (p < 0.001) at the 12 months of follow-up. Half of the patients experienced clinical improvement within the first 15 days. Treatment-related toxicity occurred in 8.9% of patients, while 26.8% required repeat radiosurgery during follow-up. The decision to perform retreatment is made when the patient has shown no improvement in the BNI score at 6 months after the initial treatment. Baseline BNI grade V was the only statistically significant predictor of treatment failure, conferring a more than ninefold higher odds of non-response compared with BNI grade IV (OR 9.33; 95% CI, 1.66–52.3; p = 0.011). Female sex showed a nonsignificant trend toward a lower risk of failure (OR 0.65; 95% CI, 0.13–3.24; p = 0.596). Neither multiple sclerosis-associated TN nor other etiological or dosimetric variables significantly predicted treatment failure. A greater number of beams showed a trend toward an increased probability of retreatment (OR 1.01; p = 0.091), although statistical significance was not reached. Conclusions: Gyroscopic radiosurgery with ZAP-X provides high rates of pain control, rapid clinical response, and a favorable safety profile in patients with refractory TN. Greater baseline pain severity appears to be associated with poorer treatment response. These findings support ZAP-X as an effective frameless radiosurgical alternative for TN, although larger prospective studies are required to identify robust clinical, dosimetric, and radiobiological predictors of long-term outcome.